Chilean Biotech Firm Advances Cancer ⁣Vaccine Trials

SANTIAGO, Chile – Oncobiomed, a biotechnology company focused on cancer prevention, diagnosis, and treatment, is making strides in clinical trials for its⁢ Tapcells and Lycellvax vaccines. These innovative treatments, developed in Chile, are showing promising early results.

“we have observed an immunological ​response in approximately 60% of patients,” said Cristian Pereda, a ​biotechnology engineer and CEO of Oncobiomed, ‍in a recent interview.

The company’s work on these treatments‍ spans over⁤ two decades, originating from a University of Chile research project initiated in 2002 to explore therapies ‌for malignant melanoma.

With two distinct technologies now developed, Oncobiomed is currently in the clinical study phase, with hopes ⁣of bringing the‍ vaccines ​to market in the near future.”If everything ​progresses as planned, we anticipate completing clinical studies in about three years, with market availability potentially delayed by an additional two years,” Pereda stated.

How the Vaccines Work

Tapcells, the more advanced of ‍the​ two vaccines, is an immunotherapy designed to ‍activate the immune system, enabling it to recognize and destroy specific tumor cells.

This ‍therapy employs⁢ a personalized approach. “Tapcells is manufactured using ⁢the patient’s own cells. We isolate these cells through leukapheresis, a‍ process where blood is extracted, purified in the laboratory, ‌and specific cell types are isolated,” Pereda explained.

Once isolated, the⁣ cells⁤ are “trained” in the lab and reintroduced to the patient in four doses ⁤over two months. Tumor lysates, a mixture of proteins and other components, are ​added to stimulate the immune system. “This process activates the patient’s ⁣cells,” Pereda said.

Clinical trials for Tapcells have involved patients with melanoma and prostate cancer.

Lycellvax, the second⁣ vaccine, shares similarities with‍ Tapcells but ‌lacks the personalized approach. “Lycellvax is more akin to a traditional drug, allowing ⁤for laboratory manufacturing and distribution⁤ to various patients without requiring a patient-specific biological sample.” This vaccine has also⁢ undergone testing ‌in melanoma patients.

Early clinical studies indicate that Tapcells‌ has demonstrated efficacy, with 60% of patients exhibiting⁤ an immunological response and a corresponding⁣ increase in‍ survival rates. This suggests the vaccine is effectively ‌activating the immune system as intended.

Pereda noted that clinical studies frequently enough involve patients with advanced, metastatic cancer (stages 3 and 4) who have limited therapeutic​ options.”Therefore, any positive reaction or effect is​ highly beneficial,” he said.

Lycellvax is currently in Phase​ 1 clinical trials, primarily focused on assessing the treatment’s⁣ safety and‍ analyzing the immune response.

Both vaccines have shown minor adverse effects, such as mild⁢ fever and injection site pain.While patients have demonstrated an immunological response to Lycellvax, the results have been mixed.

“Some patients have shown‌ progression, others‌ have stabilized, and in some cases,⁣ we have even observed tumor regression. We are still analyzing ⁤the⁣ patient results and plan to publish these studies,” Pereda said.

Accessibility and Future Steps

Oncobiomed aims to market ⁣these Chilean-developed ⁤cancer vaccines, but several steps remain. These include obtaining approval from regulatory bodies such as the Public Health Institute (ISP) in ‍Chile and ⁣potentially the Food and Drug Governance (FDA) in the ⁤United States.

“We must comply with ⁤clinical phases to demonstrate the ​treatment’s safety and beneficial effects. Once proven, it can be marketed,” ⁣Pereda explained.

The company also intends to make the treatment accessible.⁢ “Our goal is to make this treatment available to a broad⁢ population, and we believe it ⁢will be⁢ more affordable than existing immunotherapies on the market, which are very expensive,” Pereda said.

However, the ⁣final price will depend on production costs and the expenses associated with financing the clinical phases. “We still anticipate⁢ it will be a lower-cost option,” Pereda added.

Developing,‌ patenting,​ and bringing such technologies to market typically takes 15 ‍to 20 years, ‍and potentially longer in Chile due to process delays and the absence of well-defined regulatory⁤ guidelines.

“There is a lack of regulatory legislation in this area, ⁢making it challenging to advance in clinical phases. To secure funding, companies ofen need to go to⁢ the ‌United States or Europe, ⁤which⁢ is even ‌more expensive.This is a significant limitation,” Pereda ⁣said.

Despite these challenges, Oncobiomed is forging a precedent by developing the first cancer vaccines in Chile, highlighting the country’s scientific potential.

the company is also exploring collaborations with other countries, such as Brazil, to conduct further clinical studies and market the vaccines.

“We are committed to supporting our results with scientific evidence.We have been working​ diligently in the‍ laboratory to ensure the robustness‌ of‍ our research,” Pereda concluded.“We are now working to increase our visibility, which will build confidence among state agencies and investors, enabling us to secure the⁤ funding needed to continue advancing⁢ through the clinical stages.”

‌